Pharmacogenomic testing Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines pharmacogenomic testing, the use of a patient genotype to choose the drug and dose that is safest and most effective. It tests how fast preemptive testing, in which a panel is run before a prescription is needed and the result stays on the record, moves from research into health system programmes and primary care, and which participants capture value among laboratories, genotyping suppliers, decision support providers, health systems and payers.

The strongest evidence comes from the PREPARE trial, published in The Lancet in February 2023, which randomised 6,944 patients in seven European countries to a 12 gene panel with prescribing guided by Dutch Pharmacogenetics Working Group recommendations for 39 medicines. Among patients with an actionable result, 21% had a clinically relevant adverse drug reaction in the tested group against 28% in the control group, an odds ratio of 0.70. The conclusion is that genotype guided prescribing lowers the odds of a clinically relevant reaction by about 30% in patients who carry an actionable variant, and the trial team stated that the evidence supports implementation.

The burden is large. Adverse drug reactions account for about 7% of NHS hospital admissions, and a 2022 report by the Royal College of Physicians and the British Pharmacological Society found a genetic cause for differences in response to more than 40 medicines. The conclusion is that prescribing safety gives health systems a direct cost case, because each avoided admission offsets the price of a panel.

Health systems are moving from pilots to programmes. NHS Greater Glasgow and Clyde started the PHOENIX trial in April 2025, a randomised study of preemptive testing across 16 pharmacogenes for patients newly prescribed an affected drug, which tracks readmissions, medication changes and NHS cost savings, with recruitment of 2,000 to 4,000 patients and completion listed for February 2027. DPYD testing before fluoropyrimidine chemotherapy is already in the National Genomic Test Directory of England. The conclusion is that single gene tests with strong evidence are routine, and the next step is panels that serve primary care and acute care alike.

Workforce and systems hold back the pace. Sir Munir Pirmohamed has named workforce education as the main barrier, with decision support systems still immature and most community pharmacists unable to access the patient care record. The conclusion is that suppliers of electronic health record decision support and training capture a growing share of value alongside laboratories.

The brief treats pharmacogenomic testing as an accelerating category with an eight year horizon to 2034. It identifies which applications, regions and operators scale first and what each means for laboratories, genotyping suppliers, decision support providers, health systems and payers. It is a focused 102-page decision brief that presents an indicative trajectory rather than a segmented market model.

Pharmacogenomic tests read variants in genes that control how a drug is absorbed, broken down or acts, such as CYP2D6, CYP2C19 and DPYD, and report how a patient is likely to respond.

Tests are single gene, multi-gene panels of a dozen or more genes, or part of a genome. Preemptive testing runs a panel in advance and stores the result for later prescriptions.

Interpretation follows guidelines from the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group, and decision support in the electronic health record turns a genotype into a dose or drug recommendation.

Uses are prescribing in cardiology, psychiatry, pain, cancer treatment and infection, each under laboratory test rules and drug labels.

The limits are workforce education, immature decision support, inconsistent coverage and access to records. The period turns on whether trial evidence and programmes lead payers and health systems to fund preemptive testing.

The pharmacogenomic testing market, covering single gene and panel tests, genotyping consumables, laboratory services and decision support software used to guide prescribing, is valued at USD 2.5–4.0 billion in 2026 and is projected to reach USD 7.13–11.41 billion by 2034, at a CAGR of 14%.

The 2026 base rests on single gene tests, panels, genotyping consumables, laboratory services and decision support software sold to health systems, laboratories, pharmacies and consumers. Growth then follows preemptive testing programmes, payer coverage and integration in electronic health records.

The forecast is sensitive to trial results, coverage decisions and workforce readiness. Regionally, North America leads on laboratory volumes and health system programmes, Europe on trials and national programmes, and Asia-Pacific on population genotyping.

The base case assumes trials show lower hospital use and several health systems launch preemptive programmes, giving the inflection in 2030. An accelerated case assumes national programmes and broad payer coverage, bringing the inflection to 2029 and lifting the 2034 value to the top of the range. A delayed case assumes slow workforce training and inconsistent coverage, holding growth at the bottom of the range.

Growth drivers

• Trial evidence on adverse drug reactions.
• Preemptive testing programmes in health systems.
• Guidelines from CPIC and DPWG.
• Falling genotyping cost.

Enablers

• National programmes and test directories.
• Health system and laboratory partnerships.
• Electronic health record decision support.
• Pharmacist and prescriber training.

Restraints and barriers

• Workforce education.
• Immature decision support.
• Inconsistent coverage.
• Access to patient records for community pharmacists.

The direction of pharmacogenomic testing is set by the need to prevent adverse drug reactions, guidelines, labelling and regulation, panels and decision support, partnering among health systems, payers and laboratories, and genotyping cost and test price.

The key participants in pharmacogenomic testing include Myriad Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN N.V., Genomind, Inc., GeneDx Holdings Corp., Fulgent Genetics, Inc., Eurofins Scientific SE, SOPHiA GENETICS SA, Oracle Corporation, Epic Systems Corporation, Tempus AI, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Sysmex Corporation, Genomics plc, University of Liverpool, NHS Greater Glasgow and Clyde, NHS England, Genomics England, Royal College of Physicians, British Pharmacological Society, Clinical Pharmacogenetics Implementation Consortium, Dutch Pharmacogenetics Working Group, Stanford University, Mayo Clinic, Vanderbilt University Medical Center, Cleveland Clinic, UnitedHealth Group Incorporated, Centers for Medicare & Medicaid Services, U.S. Food and Drug Administration, Medicines and Healthcare products Regulatory Agency, European Medicines Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration and College of American Pathologists.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as pharmacogenomic testing matures.

Myriad Genetics, Genomind, Laboratory Corporation of America Holdings and Quest Diagnostics lead in testing services, Thermo Fisher Scientific, Illumina, QIAGEN and Agilent Technologies supply genotyping, and Oracle and Epic Systems provide the electronic health record platforms in which decision support runs. Competitive intensity is moderate in 2026 and rises as programmes widen.

Where value migrates.

In 2026 value sits with laboratories that hold panels and health system partnerships, because buyers pay for a test and a report. By 2030 it moves toward companies in electronic health record decision support and integrated programmes, because a result has value only when it reaches the prescriber at the time of prescribing. By 2034 it settles in prescribing safety platforms that join genotype, drug and patient data. Margins hold for providers with contracts and decision support and narrow for stand-alone panels sold on price.

The signals converge on evidence and programme starts. A trial of 6,944 patients found an odds ratio of 0.70, adverse drug reactions account for about 7% of NHS hospital admissions, and a new hospital trial began in April 2025. Each signal supports growth, and workforce education, decision support and coverage limit the pace.

Structural limits show where progress could slow: workforce education, immature decision support, inconsistent coverage, and access to records for community pharmacists. The brief therefore tracks four indicators: trial readouts, programme launches, payer coverage, and patients tested.

Single gene tests with strong evidence first, then multi-gene panels in acute care, then preemptive panels in primary care are the expected order of adoption.